Clinical Trials
39 trialsNCT07611110 2026-05-28
VECTRA-01
AstraZeneca
Phase 3 Recruiting
NCT04597125 2026-05-11
RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)
Bayer
Phase 4 Active not recruiting
NCT00699751 2026-02-23
ALSYMPCA
Bayer
Phase 3 Completed
NCT02141438 2025-10-16
REASSURE
Bayer
Completed
NCT04521361 2025-09-19
A Study to Assess How Radium-223 Distributes in the Body of Patients With Prostate Cancer Which Spread to the Bones
Bayer
Phase 1 Completed
NCT02803437 2025-07-10
Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone Metastases
Bayer
Completed
NCT02043678 2025-02-19
ERA 223
Bayer
Phase 3 Completed
NCT04232761 2024-07-17
RAPIT
Bayer
Completed
NCT04587427 2024-03-08
DIRECT
Bayer
Completed
NCT03315260 2024-02-08
Treatment Satisfaction With Ra-223 in Japan
Bayer
Completed
NCT04256993 2024-01-16
PRECISE
Bayer
Completed
NCT00337155 2023-11-02
BAY88-8223, Dose Finding Study in Patients With HRPC
Bayer
Phase 2 Completed
NCT04681144 2023-10-26
QOLRAD
Bayer
Completed
NCT05301062 2023-09-22
CREDIT
Bayer
Terminated
NCT00667199 2023-04-19
BAY88-8223, Does Response Study in HRPC Patients
Bayer
Phase 2 Completed
NCT04281147 2022-06-23
REACTIVATE
Bayer
Completed
NCT04516161 2022-03-31
EPIX
Bayer
Completed
NCT03896984 2021-12-29
PHENIX
Bayer
Completed
NCT02398526 2021-11-02
PARABO
Bayer
Completed
NCT02450812 2021-11-02
URANIS
Bayer
Completed
NCT03419442 2020-10-22
Multi-academic Center Study of Xofigo Patients
Bayer
Completed
NCT03563014 2020-05-20
BELFIGO
Bayer
Completed
NCT02899104 2020-03-31
Navigant
Bayer
Completed
NCT02814669 2019-09-24
Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor
Hoffmann-La Roche
Phase 1 Completed
NCT02034552 2019-07-23
A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)
Bayer
Phase 2 Completed
NCT02023697 2019-07-12
Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone
Bayer
Phase 2 Completed
NCT03325127 2018-10-31
Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review Study
Bayer
Withdrawn
NCT01810770 2018-09-19
Radium-223 Dichloride Asian Population Study in the Treatment of CRPC Patients With Bone Metastasis
Bayer
Phase 3 Completed
NCT02518698 2018-09-18
Treatment Patterns in Castrate Resistant Prostate Cancer Patients With Bone Metastases in a Medicare Population
Bayer
Completed
NCT01929655 2018-04-24
Japanese BAY88-8223 Monotherapy Phase II Study
Bayer
Phase 2 Completed
NCT01934790 2018-03-26
Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone Metastases
Bayer
Phase 1/2 Completed
NCT02729103 2018-01-25
Treatment Patterns in Metastatic Prostate Cancer
Bayer
Completed
NCT01618370 2017-03-31
Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases
Bayer
Phase 3 Completed
NCT01106352 2017-01-04
A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)
Bayer
Phase 1/2 Completed
NCT01565746 2016-10-17
Safety, Biodistribution, Radiation Dosimetry and Pharmacokinetics Study of BAY88-8223 in Japanese Patients
Bayer
Phase 1 Completed
NCT00667537 2015-12-14
PK in Pts With HRPC & Skeletal Metastes
Bayer
Phase 1 Completed
NCT01516762 2014-07-14
Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases
Bayer
No longer available
NCT00459654 2014-06-25
A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate Cancer
Bayer
Phase 2 Completed
NCT00748046 2014-06-25
Alpharadinâ„¢ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton
Bayer
Phase 1 Completed